Elpida (elsulfavirine) / Viriom  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Elpida (elsulfavirine) / Viriom
NCT03625388: Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Completed
2
56
RoW
Dasatinib, Elpida®
Hikma Pharmaceuticals LLC
Chronic Myelogenous Leukemia
07/23
07/23
NCT02485509: Study of Safety and Pharmacokinetics in Healthy Volunteers and Safety, Tolerability and Antiviral Activity of VM-1500 in Patients With Human Immunodeficiency Virus-1 Infection

Completed
1/2
28
RoW
VM-1500/Placebo
Viriom
HIV Infection
12/13
12/13
NCT05163535: Open Labelled, Randomized Study to Evaluate the Efficacy, Safety and Dose Selection of VM-1500A-LAI Drug in HIV-infected Patients Transferred From Previous Stable Therapy (NNRTI + 2NRTI), Including ELPIDA®

Completed
1/2
36
RoW
VM-1500A-LAI, VM-1500A, VM-1500, ELPIDA®
Viriom
HIV-1-infection
08/21
08/21

Download Options